By day 5, we observed >800-fold more CD8+ tumor-infiltrating lymphocytes (TILs) in tumors treated with PD1d/IL-2v/IL-33 OT1 relative to non-treated B16-OVA tumors (Extended Data Fig. 3a,b). This evidence concerns the gene CD8A and neoplasm.